Hodgkin's lymphoma: a treatment with results "spectacular "
Patients with a rare form of blood cancer very difficult to treat have seen the progression of their disease stopped by a very promising treatment.
Visualization of Hodgkin's lymphoma metastasized performed by PET Scan (positron emission tomography) at the Chu in Lille. Visualization of a Hodgkin's lymphoma metastasized carried out by PET scan (positron emission tomography) at CHU Lille. I M N/CHU LILLE/BSIP/AFP
Treatment. A new treatment marketed in the United States and Europe significantly increases the chances of survival of patients with Hodgkin's lymphoma, a blood cancer that strikes mainly young adults, according to a study published Thursday, March 19, 2015 the Lancet Diabetes and Endocrinology. It is the brentuximab vedotin (marketed under the brand Adcetris by the Takeda Laboratory), the first new treatment developed in the space of 30 years against Hodgkin's lymphoma, stresses the British journal. This product is a complex monoclonal antibody capable of recognizing the specific antigens expressed by cancer cells.
Most patients with Hodgkin's lymphoma usually respond to chemotherapy and radiation therapy. But a minority of them reoffend or become refractory to treatment and are offered other treatments, such as stem cell transplants, which do not always allow them to be cured. Presented as a treatment of remedies in this type of case, the Adcetris received an authorisation to put on the US market in 2011 and another "conditional " In 2012 for the European market, pending additional data.
Hodgkin's lymphoma is a type of blood cancer that affects the lymphatic system involved in the body's immune response. Abnormal lymphocytes, a type of white blood cells supposed to fight infections, are transformed into cancerous cells, which multiply and accumulate in the lymph nodes. Over time, these cells compromise the immune system. The organism loses a part of its system of defense against viruses and bacteria and therefore infections occur more easily.
No medicine had yet shown such spectacular results "-Dr. Moskowitz
In their phase III clinical trial, researchers led by American oncologist Craig Moskowitz stated that they had tested the drug on 329 patients at high risk of relapse after a stem cell transplant. Two years later, cancer had not increased in 65% of patients treated with brentuximab vedotin compared to only 45% in the placebo group. Survival without progression of the disease for two years is considered a good indication of a possible cure.
0 comments:
Post a Comment